? CLINICAL-TRANSLATIONAL SCIENCE SHARED RESOURCE (CTSSR) The goal of the CTSSR is to foster the clinical-translational mission of OSUCCC members without wet- laboratories by providing support and short-term needs for correlative science and other testable hypotheses. The CTSSR is a consultative project management and central laboratory service that was developed with a focus on investigator-initiated solid tumor clinical trials, but now supports all types of dry laboratory researchers (hematological malignancy and population scientists). During the current funding cycle, the CTSSR, formerly known as the Solid Tumor Translational developing Shared Resource (SR) was funded through CCSG development funds, and is now being proposed as a full CCSG SR.
The Specific Aims of the CTSSR are to: 1) provide project design and project management support (including navigation, protocol development, grant application and manuscript preparation) for studies that utilize resources available through other OSUCCC SRs, investigator laboratories, and outside vendors; 2) provide specific laboratory services and sample processing support for clinical translational research; and, 3) develop and rigorously perform customized laboratory assays to meet the short-term needs of clinical investigators for a specific protocol, a specified time, or a specified number of patient samples. Conveniently located within the Biomedical Research Tower, the CTSSR is accessible to most OSUCCC clinicians and tissue procurement services. Major equipment includes a cell culture facility, a QX200 Droplet Digital PCR System-Bio Rad and a Promega Maxwell RSC for high throughput nucleic acid purification, and a Luminex Magpix for multiplex protein assays. During the current grant period, the CTSSR has supported 94 investigators (62% OSUCCC members), and provided 8,223 hours of service and processed 3,602 samples (82.9% to OSUCCC members). The CTSSR provided services in support of 72 publications (14 > 10 impact factor), 94 users, and 9 NCI grants, including 1 K01, 2 P01s, 1 P50, 4 R01s, and 1 R03. The CTSSR currently supports 20 ongoing trials and there are 8 new ones in the pipeline (spanning all five programs). It is anticipated that the CTSSR will expand rapidly due to the continued rapid growth of the OSUCCC with its strategic priorities. Specific future plans include participating in the developing Immune Monitoring and Discovery Platform, fostering interactions with other shared resources for immuno-oncology projects; increase support for hematologic and population science studies; establish a cell culture facility to enable preclinical cancer cell culture studies (including drug synergy) needed as pilot data for human studies applications; and provide multiplex protein arrays for human studies using whole cells, cell/tumor extracts and other biological fluids. The annual budget of the CTSSR is $552,510, yet the CCSG request is $60,723. As such, The CTSSR leverages extensive institutional support and seeks only 11% support from CCSG funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509

Showing the most recent 10 out of 2602 publications